EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium

Evelien Gielen, Martina Aldvén, John A Kanis, Fredrik Borgström, Emmanuelle Senior, Damon Willems

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07043-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, 2024. Verfasst von Evelien Gielen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, UZ Leuven, Louvain, Belgium. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Osteoporotic Fractures, Bone Density Conservation Agents, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma, Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the cost-effectiveness of sequential treatment with romosozumab-to-alendronate compared to alendronate monotherapy and teriparatide-to-alendronate, in postmenopausal osteoporotic women from a Belgian healthcare perspective. Romosozumab-to-alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide-to-alendronate for osteoporotic women at high risk of fracture in Belgium. PURPOSE: This study aimed to evaluate the cost-effectiveness of sequential treatment with romosozumab followed by alendronate compared to alendronate monotherapy and teriparatide followed by alendronate, in postmenopausal osteoporotic women at high risk of fracture, from a Belgian healthcare perspective. Romosozumab is reimbursed in Belgium since December 2021. METHODS: A Markov microsimulation model was used to evaluate the cost-effectiveness of romosozumab-to-alendronate compared to alendronate monotherapy and to teriparatide-to-alendronate over a lifetime horizon. Patients transition between five different health states every 6 months based on fracture risks or death. The model was populated with Belgium-specific epidemiological and cost data, where available. The fracture risk reduction of romosozumab treatment was collated from the ARCH study, and from a published network meta-analysis. Costs were included from a healthcare perspective (NIHDI). Cost-effectiveness was reported in terms of costs per quality-adjusted life year (QALY), reported in Euro (€) 2022. Deterministic (DSA) and probabilistic sensitivity analyses (PSA) were performed. RESULTS: Romosozumab-to-alendronate was associated with 0.12 additional QALYs at an additional cost of €2314 compared to alendronate monotherapy, resulting in an ICER of €19,978. Compared to teriparatide-to-alendronate, romosozumab-to-alendronate was found to be dominant, with higher QALYs and lower costs. The base-case results were robust to uncertainty in the input parameters when conducting the sensitivity analysis. CONCLUSION: Sequential treatment with romosozumab followed by alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide followed by alendronate for postmenopausal women with osteoporosis at high risk of fracture in Belgium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisOsteoporotic FracturesBone Density Conservation AgentsOsteoporosis, PostmenopausalQuality-Adjusted Life YearsMarkov ChainsAlendronateTeriparatideDrug CostsAntibodies, MonoclonalHumansFemaleBelgiumAgedDrug Therapy, CombinationMiddle AgedDrug Administration ScheduleDrug Substitution

Stichwörter der Autor:innen

Cost-effectivenessEconomic evaluationImminent fracture riskMarkov-microsimulation modelOsteoporosisRecent fracture

Substanzen

Bone Density Conservation AgentsromosozumabAlendronateTeriparatideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Geriatrics, UZ Leuven, Louvain, Belgium.
  • Geriatrics & Gerontology, Department of Public Health and Primary Care, KU Leuven, Louvain, Belgium.
  • Quantify Research, Stockholm, Sweden.
  • University of Sheffield, Sheffield, UK.
  • Mary MacKillop Health Institute, Catholic University of Australia, Melbourne, Australia.
  • UCB Pharma, Brussels, Belgium.

Förderung

  • UCB Pharma
  • Amgen Inc

Zitieren

APA

Gielen, E., Aldvén, M., Kanis, J. A., Borgström, F., Senior, E., & Willems, D. (2024). Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporosis International. https://doi.org/10.1007/s00198-024-07043-2

Vancouver

Gielen E, Aldvén M, Kanis JA, Borgström F, Senior E, Willems D. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporosis International. 2024. doi:10.1007/s00198-024-07043-2

BibTeX
@article{Gielen2024,
  author = {Gielen, Evelien and Aldvén, Martina and Kanis, John A and Borgström, Fredrik and Senior, Emmanuelle and Willems, Damon},
  title = {Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07043-2}
}
Kostenlos starten →